Gene therapy represents a new potential avenue for the treatment of retinal diseases, including age-related macular degeneration, according to a presenter at the virtual OSN New York Retina meeting.
“Gene therapy is an exciting new treatment approach in the field of ophthalmology where we can use viral vectors that carry the gene of interest into the host cell,” Aleksandra Rachitskaya, MD, of the Cole Eye Institute, said.
Two therapies undergoing trials for treatment of neovascular age-related macular degeneration, RGX-314 (Regenxbio) delivered subretinally and ADVM-022 (Adverum
Uncategorized